SPRY logo

SPRY
ARS Pharmaceuticals Inc

2,448
Mkt Cap
$853.96M
Volume
1.13M
52W High
$18.90
52W Low
$6.66
PE Ratio
-4.97
SPRY Fundamentals
Price
$8.63
Prev Close
$8.60
Open
$8.64
50D MA
$8.37
Beta
1.25
Avg. Volume
1.53M
EPS (Annual)
-$1.74
P/B
7.50
Rev/Employee
$517,042.95
$1,000.28
Loading...
Loading...
News
all
press releases
Cronos Group (CRON) Q1 Earnings Meet Estimates
Cronos (CRON) delivered earnings and revenue surprises of 0.00% and +6.94%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2d ago
News Placeholder
More News
News Placeholder
Collegium Pharmaceutical (COLL) Q1 Earnings and Revenues Beat Estimates
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of +23.94% and +7.01%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·6d ago
News Placeholder
Earnings Preview: ARS Pharmaceuticals, Inc. (SPRY) Q1 Earnings Expected to Decline
ARS Pharmaceuticals, Inc. (SPRY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·7d ago
News Placeholder
ARS Pharmaceuticals (SPRY) Projected to Post Quarterly Earnings on Wednesday
ARS Pharmaceuticals (NASDAQ:SPRY) will be releasing its Q1 2026 earnings before the market opens on Wednesday, May 13. (View Earnings Report at...
MarketBeat·7d ago
News Placeholder
Q1 Earnings Forecast for SPRY Issued By Northland Securities
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) - Analysts at Northland Securities issued their Q1 2026 EPS estimates for ARS Pharmaceuticals in a research note issued to investors on Thursday...
MarketBeat·1mo ago
News Placeholder
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Consensus Recommendation of "Hold" by Analysts
Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Get Free Report) have earned a consensus recommendation of "Hold" from the five analysts that are presently covering the stock, Marketbeat Ratings...
MarketBeat·1mo ago
News Placeholder
ARS Pharmaceuticals (NASDAQ:SPRY) Coverage Initiated by Analysts at Northland Securities
Northland Securities initiated coverage on shares of ARS Pharmaceuticals in a report on Thursday. They issued an "outperform" rating and a $25.00 price target on the stock...
MarketBeat·1mo ago
News Placeholder
Aberdeen Group plc Purchases 459,027 Shares of ARS Pharmaceuticals, Inc. $SPRY
Aberdeen Group plc raised its position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 14.8% during the fourth quarter, according to its most recent disclosure with the Securities and...
MarketBeat·1mo ago
News Placeholder
ARS Pharmaceuticals (NASDAQ:SPRY) Shares Up 8% - Should You Buy?
ARS Pharmaceuticals (NASDAQ:SPRY) Shares Up 8% - Should You Buy...
MarketBeat·2mo ago
News Placeholder
ARS Pharmaceuticals (NASDAQ:SPRY) Shares Down 5.7% - Time to Sell?
ARS Pharmaceuticals (NASDAQ:SPRY) Shares Down 5.7% - Here's What Happened...
MarketBeat·2mo ago
<
1
2
...
>

Latest SPRY News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.